Loss-of-function mutations were observed in KMT2D (~90% of FL and ~30% of DLBCL)97,98, CREBP, or the EP300 that have been reported in 40% of DLBCL and FL patients97. Here, EP300 is linked to diffuse large B-cell lymphoma.